Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 5.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,084,727 shares of the company’s stock after purchasing an additional 57,016 shares during the period. Geode Capital Management LLC owned 1.82% of Pyxis Oncology worth $3,982,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in PYXS. MetLife Investment Management LLC boosted its position in shares of Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after buying an additional 5,484 shares during the period. Pier 88 Investment Partners LLC boosted its position in Pyxis Oncology by 7.0% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock worth $446,000 after acquiring an additional 7,910 shares during the period. Jane Street Group LLC boosted its position in Pyxis Oncology by 40.8% during the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after acquiring an additional 14,349 shares during the period. Intech Investment Management LLC purchased a new position in Pyxis Oncology during the 3rd quarter valued at about $55,000. Finally, SG Americas Securities LLC acquired a new position in shares of Pyxis Oncology in the 3rd quarter valued at about $58,000. 39.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Finally, Stephens began coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.43.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS opened at $1.70 on Monday. The business’s 50-day simple moving average is $2.56 and its 200-day simple moving average is $3.14. Pyxis Oncology, Inc. has a 52 week low of $1.49 and a 52 week high of $6.85. The firm has a market cap of $101.09 million, a price-to-earnings ratio of -1.65 and a beta of 1.00.

Insiders Place Their Bets

In other Pyxis Oncology news, CFO Pamela Ann Connealy purchased 88,850 shares of the stock in a transaction dated Tuesday, November 26th. The shares were bought at an average cost of $1.96 per share, with a total value of $174,146.00. Following the completion of the transaction, the chief financial officer now owns 1,199,143 shares in the company, valued at $2,350,320.28. This trade represents a 8.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 9.80% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.